the risk of hypercalcemia with lithium therapy

Health Canada is warning about the risk of hypercalcemia with lithium therapy (Carbolith, etc).

Lithium is still used for patients with bipolar disorder to prevent relapses and for its antimanic effect.

But about 10% of patients on long-term lithium develop hypercalcemia...and some also develop hyperparathyroidism.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote